Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPL554 pMDI in COPD
NCT04091360Phase 2Completed
- Sponsor
- Verona Pharma
- Start
- Apr 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ensifentrine in chronic obstructive pulmonary disease (COPD), sponsored by Verona Pharma. Started Apr 2019; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04091360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091360.